Magaldrate
Clinical data | |
---|---|
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a682683 |
Pregnancy category |
|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | Negligible |
Metabolism | Nil |
Excretion | Fecal and renal |
Identifiers | |
| |
CAS Number | |
ECHA InfoCard | 100.115.465 |
Chemical and physical data | |
Formula | AlMg2(OH)7·H2O |
Molar mass | 212.66 g/mol |
| |
(verify) |
Magaldrate (INN) is a common antacid drug that is used for the treatment of duodenal and gastric ulcers, esophagitis from gastroesophageal reflux.
Development
[edit]Magaldrat was first synthesized by the German chemist Gunther Hallmann and patented on February 2, 1960, by Byk Gulden Lomberg Chemische Fabrik (Germany).[1] In 1983, the active substance was registered as the original drug Riopan.[2]
Available forms
[edit]Magaldrate is available in the form of oral suspension or tablets.
Pharmacology
[edit]Magaldrate is a hydroxymagnesium aluminate complex that is converted rapidly by gastric acid into Mg(OH)2 and Al(OH)3, which are absorbed poorly and thus provide a sustained antacid effect.[3]
Interactions and adverse reactions
[edit]Magaldrate may negatively influence drugs like tetracyclines, benzodiazepines, and indomethacin. High doses or prolonged usage may lead to an increment of defecation and a reduction in feces consistence. In some cases it can alter the functionality of the gastrointestinal tract, occasionally provoking constipation or diarrhea.
References
[edit]This article needs additional citations for verification. (September 2014) |
- ^ US patent 2923660, Hallmann G, "Process for the preparation of magnesium aluminate hydrate, and therapeutic agents so produced", issued 1960-02-02, assigned to Byk Gulden Lomberg Chem. Fab.
- ^ Fachinfo Riopan Magen Tabletten, Stand Dezember 2014.
- ^ Laurence BL. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th ed.